Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Yu, JY; Tostanoski, LH; Mercado, NB; McMahan, K; Liu, JY; Jacob-Dolan, C; Chandrashekar, A; Atyeo, C; Martinez, DR; Anioke, T; Bondzie, EA; Chang, AQ; Gardner, S; Giffin, VM; Hope, DL; Nampanya, F; Nkolola, J; Patel, S; Sanborn, O; Sellers, D; Wan, HH; Hayes, T; Bauer, K; Pessaint, L; Valentin, D; Flinchbaugh, Z; Brown, R; Cook, A; Bueno-Wilkerson, D; Teow, E; Andersen, H; Lewis, MG; Martinot, AJ; Baric, RS; Alter, G; Wegmann, F; Zahn, R; Schuitemaker, H; Barouch, DH

Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.

NATURE, 2021; 596 (7872): 423

Abstract

The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines(1,2). Th......

Full Text Link